Differences in TP53 Mutation Carrier Phenotypes Emerge From Panel-Based Testing-Reference-Cited by-同舟云学术

Differences in TP53 Mutation Carrier Phenotypes Emerge From Panel-Based Testing

Published:2018-02-26 Issue:8 Volume:110 Page:863-870
ISSN:0027-8874
Container-title:JNCI: Journal of the National Cancer Institute
language:en
Short-container-title:

Author:

Rana Huma Q¹²,Gelman Rebecca³²,LaDuca Holly⁴,McFarland Rachel⁴,Dalton Emily⁴,Thompson Jennifer⁴,Speare Virginia⁴,Dolinsky Jill S⁴,Chao Elizabeth C⁴⁵,Garber Judy E¹²

Affiliation:

1. Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

2. Harvard Medical School, Boston, MA

3. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA

4. Ambry Genetics, Aliso Viejo, CA

5. Division of Genetics and Genomics, University of California, Irvine, Irvine, CA

Funder

Dana-Farber/Harvard Cancer Center

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/110/8/863/25452262/djy001.pdf

Reference58 articles.

1. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?;Li;Ann Intern Med,1969

2. Genetic and pathologic findings in a kindred with hereditary sarcoma, breast cancer, brain tumors, leukemia, lung, laryngeal, and adrenal cortical carcinoma;Lynch;Cancer.,1978

3. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms;Malkin;Science.,1990

4. Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment;Desmond;JAMA Oncol.,2015

5. Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2;Minion;Gynecol Oncol.,2015

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HER2 status and response to neoadjuvant anti-HER2 treatment among patients with breast cancer and Li-Fraumeni syndrome;European Journal of Cancer;2024-11

2. Pedigree analysis exploring the inconsistency between diverse phenotypes and testing criteria for germline TP53 mutations in Chinese women with breast cancer;Breast Cancer Research and Treatment;2024-06-15

3. Clinical management of TP53 mosaic variants found on germline genetic testing;Cancer Genetics;2024-06

4. Identification of TP53 germline variants in pediatric patients undergoing tumor testing: strategy and prevalence;JNCI: Journal of the National Cancer Institute;2024-05-03

5. TP53-associated early breast cancer: new observations from a large cohort;JNCI: Journal of the National Cancer Institute;2024-04-03